Vañó-Galván, Sergio
Egeberg, Alexander
Piraccini, Bianca Maria
Marwaha, Simran
Reed, Catherine
Johansson, Erin
Durand, Frederick
Bewley, Anthony
Funding for this research was provided by:
Eli Lilly and Company
Article History
Received: 4 December 2023
Accepted: 28 February 2024
First Online: 21 March 2024
Declarations
:
: Sergio Vañó-Galván reports consulting fees and payment/honoraria from Pfizer and Lilly. Alexander Egeberg reports grants from Abbvie, Danish Nathional Psoriasis Foundation, Eli Lilly, Janssen, Kgl. Hofbundtmager Aage Bangs Foundation, Novartis, Pfizer, Boehringer Ingelheim, Bristol-Myers Squibb, Almirall and Simon Spies Foundation in relation to research funding. Consulting fees from AbbVie, Almirall, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly, Galderma, Galapagos NV, Janssen, LEO Pharma, Mylan, Novartis, Pfizer, Samsung Bioepis Co., Ltd., UCB, Union Therapeutics and Horizon Therapeutics. Payment/honoraria from AbbVie, Almirall, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Boehringer Ingelheim, Bristol-Myers Squibb, Dermavant, Eli Lilly, Galderma, Janssen, LEO Pharma, Mylan, Novartis, Pfizer, Samsung Bioepis Co., Ltd. and UCB. Support for attending congresses from Abbvie, Eli Lilly, Bristol-Myers Squibb and Janssen. Participation on a Data Safety Monitoring Board or Advisory Board from Samsung Bioepis and Horizon Therapeutics. Bianca Maria Piraccini received payment/honoraria from Pierre fabre-Ducray, ISDIN, Legacy Healthcare, Pfizer, Almirall, Eli Lilly, Difa Cooper and Dercos-L’Oreal. Simran Marwaha is an employee of Adelphi Real World. Anthony Bewley reports royalties from Wiley. Ad hoc consultancy with Abbvie, Almirall, Lilly, UCB, Pfizer, Sanofi, Leo Pharma, Galderma, Janssen, Novartis and BMS. Travel support to attend congresses from Almirall, Lilly, Janssen. Catherine Reed, Erin Johansson and Frederick Durandare employees and minor shareholders of Eli Lilly and Company.
: Data collection was undertaken in line with European Pharmaceutical Marketing Research Association guidelines (EphMRA) and as such it did not require institutional review board (IRB)/independent ethics committee approval. The DSP was performed in full accordance with relevant legislation at the time of data collection, including the US Health Insurance Portability and Accountability Act 1996. However, the AA DSP was submitted to the Western IRB for methodological review in 2019 and was granted an exemption. The DSP was conducted in compliance with the International Council for Harmonization Declaration of Helsinki. Freely given, specific and informed consent was obtained from each respondent to take part in the DSP and for the processing of their personal data. All data provided by physicians and patients were anonymized. Physicians were compensated for their participation according to fair market research rates.